Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. Company
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo HUTCHMED (China) Limited
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Number of employees : 1 280 people.
Sales per Business
2020
Other Ventures1 364.9977.2%
Oncology/Immunology - Marketed Products137.727.8%
Oncology/Immunology - Research and Development70.834%
HKD in Million
Sales per region
2020
China1 573.5489%
HKD in Million
Managers
Name Title Age Since
Christian Hogg Chief Executive Officer & Executive Director 55 2006
Chig Fung Cheng Chief Financial Officer 54 2008
Wei Guo Su Executive Director & Chief Scientific Officer 63 2017
Marek Kania Chief Medical Officer & Managing Director - -
Karen Atkin Chief Operating Officer & Executive Vice President - 2021
Paul Rutherford Carter Senior Independent Non-Executive Director 60 2017
Karen Jean Ferrante, Dr. Independent Non-Executive Director 63 2017
Graeme Allan Jack Independent Non-Executive Director 70 2017
Tony Mok, Dr. Independent Non-Executive Director 60 2017
Mark Lee Senior VP-Corporate Finance & Development 43 -
Members of the board
Name Title Age Since
Chi Keung To Executive Director 69 2000
Christian Hogg Chief Executive Officer & Executive Director 55 2006
Edith Shih Secretary & Non-Executive Director 68 2006
Chig Fung Cheng Chief Financial Officer 54 2008
Wei Guo Su Executive Director & Chief Scientific Officer 63 2017
Dan Eldar, Dr. Non-Executive Director 67 2016
Paul Rutherford Carter Senior Independent Non-Executive Director 60 2017
Karen Jean Ferrante, Dr. Independent Non-Executive Director 63 2017
Graeme Allan Jack Independent Non-Executive Director 70 2017
Tony Mok, Dr. Independent Non-Executive Director 60 2017
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 864,530,850 443,403,620 51.3% 0 0.0% 51.3%
Shareholders
NameEquities%
CK Hutchison Holdings Limited 332,574,650 38.5%
The Carlyle Group LP (Global Private Equity) 40,847,500 4.73%
Canada Pension Plan Investment Board 26,883,270 3.11%
Baring Private Equity Asia Ltd. 25,993,445 3.01%
General Atlantic LLC 25,835,000 2.99%
Christian Hogg 11,278,195 1.30%
Norges Bank Investment Management 10,248,088 1.19%
FIL Investment Management (Hong Kong) Ltd. 10,045,660 1.16%
JPMorgan Asset Management (Asia Pacific) Ltd. 7,932,785 0.92%
The Vanguard Group, Inc. 7,589,225 0.88%
Holdings
NameEquities%Valuation
EPIZYME, INC. (EPZM) 0 0.0000%
Company contact information
HUTCHMED (China) Ltd.
Cheung Kong Center
2 Queen's Road Central
48th Floor
Hong Kong

Phone : +852.2128.1188
Fax : +852.2128.1778
Web : http://www.hutch-med.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of HUTCHMED (China) Limited
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
HUTCHMED (CHINA) LIMITED-23.68%4 662
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963
NOVO NORDISK A/S-17.16%210 749
MERCK & CO., INC.2.86%199 120
NOVARTIS AG-4.40%187 626
ASTRAZENECA PLC-4.17%173 383
BRISTOL-MYERS SQUIBB COMPANY0.42%138 972
AMGEN INC.0.49%127 343
SANOFI-0.07%125 716
GLAXOSMITHKLINE PLC0.50%109 325
BAYER AG6.38%55 573
CHUGAI PHARMACEUTICAL CO., LTD-1.15%53 303
TAKEDA PHARMACEUTICAL COMPANY LIMITED6.47%45 679
DAIICHI SANKYO CO., LTD.-11.13%43 749
JIANGSU HENGRUI MEDICINE CO., LTD.-14.63%43 570
ASTELLAS PHARMA INC.2.94%31 326
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-19.40%19 699